FDA path Rolling BLA submission for MCO-010 in RP with Fast Track and Orphan Drug designations signals potential near-term US market access, presenting a sales opportunity to align with payer adoption timelines and clinical pathways.

One-time therapy MCO-010 is positioned as a one-time, in-office injection without genetic testing, which can simplify treatment workflows for retina specialists and reduce long-term patient management costs, enabling value-based selling to clinics and payers.

Expansion pipeline Active and expanding IND-ready programs across RP, SD, GA, LCA, and other retinal dystrophies create multiple cross-sell and market-entry opportunities for ophthalmology distributors and contract manufacturing/support partners.

Commercial readiness Recent partnerships for US commercialization services with InspiroGene via McKesson indicate readiness to scale, providing a channel strategy to accelerate market access, logistics, and provider education.

Clinical momentum Positive Phase 2b/2 results and upcoming Phase 3 plans, coupled with FDA and EMA designations, signal strong clinical validation and market credibility that can be leveraged in outreach to key ophthalmology networks, KOLs, and patient advocacy groups.